ANTIPLATELET THERAPY WITH CLOPIDOGREL TAKING INTO ACCOUNT CYP2C19 GENETIC POLYMORPHISMS IN PATIENTS WITH CORONARY HEART DISEASE AFTER CORONARY ARTERY STENTING

被引：1
|
作者：
Uzokov, J. [1 ]
Alyavi, B. [2 ]
Abdullaev, A. [1 ]
Muxitdinova, O. [2 ]
Ubaydullaeva, Z. [1 ]
机构：
[1] Republican Specialized Sci Pact Med Ctr Therapy &, Cardiol, Tashkent, Uzbekistan
[2] Tashkent Pediat Med Inst, Cardiol, Tashkent, Uzbekistan
来源：
ATHEROSCLEROSIS | 2021年 / 331卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P652
引用
收藏
页码：E265 / E265
页数：1
相关论文
共 50 条
  • [21] PLATELET REACTIVITY AFTER CLOPIDOGREL IN JAPANESE PATIENTS WITH CORONARY ARTERY DISEASE UNDERGOING PERCUTANEOUS CORONARY INTERVENTION ACCORDING TO CYP2C19 GENOTYPES
    Toma, Yuichiro
    Sakai, Koyu
    Noguchi, Masahiko
    Sato, Koji
    Enomoto, Soichiro
    Kato, Masashi
    Yokoi, Hiroyoshi
    Iwabuchi, Masashi
    Nosaka, Hideyuki
    Nobuyoshi, Masakiyo
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (14) : E1209 - E1209
  • [22] Association between CYP2C19*2/*3 Polymorphisms and Coronary Heart Disease
    Zhang, Ying-ying
    Zhou, Xin
    Ji, Wen-jie
    Liu, Ting
    Ma, Jing
    Zhang, Ying
    Li, Yu-ming
    CURRENT MEDICAL SCIENCE, 2019, 39 (01) : 44 - 51
  • [23] Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease
    Erlinge, David
    James, Stefan
    Duvvuru, Suman
    Jakubowski, Joseph A.
    Wagner, Henrik
    Varenhorst, Christoph
    Tantry, Udaya S.
    Brown, Patricia B.
    Small, David
    Moser, Brian A.
    Sundseth, Scott S.
    Walker, Joseph R.
    Winters, Kenneth J.
    Gurbel, Paul A.
    THROMBOSIS AND HAEMOSTASIS, 2014, 111 (05) : 943 - 950
  • [24] Association between CYP2C19*2/*3 Polymorphisms and Coronary Heart Disease
    Ying-ying Zhang
    Xin Zhou
    Wen-jie Ji
    Ting Liu
    Jing Ma
    Ying Zhang
    Yu-ming Li
    Current Medical Science, 2019, 39 : 44 - 51
  • [25] Haplotype analyses of CYP2C19*2 and CYP2C19*17 genetic polymorphisms in clopidogrel non-responsiveness after percutaneous coronary intervention with stent implantation
    Saydam, F.
    Degirmenci, I.
    Birdane, A.
    Ozdemir, M.
    Ozbayer, C.
    Ata, N.
    Gunes, H. V.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2018, 26 : 683 - 683
  • [26] Effects of CYP2C19 Genotype on Arterial Wall Properties in Patients with Coronary Artery Disease Receiving Clopidogrel
    Zaromitidou, Marina
    Tousoulis, Dimitris
    Siasos, Gerasimos
    Kioufis, Stamatios
    Oikonomou, Evangelos
    Maniatis, Konstantinos
    Miliou, Antigoni
    Gouliopoulos, Nikolaos
    Athanasiou, Dimitrios
    Dimitropoulos, Efstathios
    Vavuranakis, Manolis
    Aggeli, Constantina
    Papavassiliou, Athanasios G.
    Stefanadis, Christodoulos
    CIRCULATION, 2012, 126 (21)
  • [27] CLINICAL OUTCOMES OF CYP2C19 GENOTYPE GUIDED ANTIPLATELET THERAPY IN PATIENTS ON LONG-TERM CLOPIDOGREL THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION
    Patel, Rajiv
    Kulick, Natasha
    Winget, Marshall
    Nguyen, Anh
    Venkatesh, Sanjay
    Rossi, Joseph
    Lee, Craig R.
    Stouffer, George A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 788 - 788
  • [28] Response to clopidogrel in patients with coronary artery disease is associated with CYP2C19 but not CYP2B6 genotype.
    Nystrom, P.
    Desta, Z.
    Jakubowski, J.
    Li, L.
    Hilligoss, J.
    Tisdale, J. E.
    Kreutz, Y.
    Miao, J.
    Flockhart, D. A.
    Kovacs, R.
    Jin, Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S9 - S9
  • [29] The impact of CYP2C19 *2 and *3 polymorphism on clopidogrel response following coronary stenting in Saudi patients with acute coronary syndrome
    Khalaf H
    Al Meman A
    Rasool S
    BMC Genomics, 15 (Suppl 2)
  • [30] Response to clopidogrel in patients with coronary artery disease is associated with CYP2C19 but not CYP2B6 genotype.
    Nystrom, P.
    Desta, Z.
    Jakubowski, J.
    Li, L.
    Hilligoss, J.
    Tisdale, J. E.
    Kreutz, Y.
    Miao, J.
    Flockhart, D. A.
    Kovacs, R.
    Jin, Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S3 - S4
12345